<DOC>
	<DOCNO>NCT02145182</DOCNO>
	<brief_summary>The purpose study determine Eculizumab safe could use prevent delayed graft function follow kidney transplantation .</brief_summary>
	<brief_title>Prevention Delayed Graft Function Using Eculizumab Therapy ( PROTECT Study )</brief_title>
	<detailed_description />
	<mesh_term>Delayed Graft Function</mesh_term>
	<criteria>Subject male female , 18 year old Subject dialysis dependent renal failure ( initiated 2 month prior transplant ) Subject receive first kidney transplant SCD ECD decease donor DGF risk score use Irish scale â‰¥ 25 % ( determine prior surgery randomization ) Subject able provide write informed consent Subject must willing able comply requirement study protocol Female subject childbearing potential must negative serum pregnancy test ( serum betahCG ) must practice effective , reliable , medically approve contraceptive regimen time consent 5 month follow discontinuation treatment Subject receive multiorgan transplant Subject receive kidney ( ) donor &lt; 6 year age Subject receive dual kidney transplant ( donor , include en bloc ) Subject receive live donor kidney Subject highly sensitize ( high risk develop acute AMR ) donor ( determined local center practice ) . Testing determine high risk may include limited Flow cytometric cross match , single antigen bead test and/or complement dependent cytotoxicity Subject receive previous transplant Subject participate another investigational study Subject body mass index ( BMI ) &gt; 40 kg/m2 screen Subject recipient A , B , O Blood Glycoproteins ( ABO ) ( blood type ) incompatible kidney ( A2 donor B O recipient allow site ability confirm A2 subtype ) Subject receive kidney donation cardiac death ( DCD ) donor Subject predict Irish model risk DGF &lt; 25 % Female subject pregnant breast feed Female subject child bear potential unable unwilling use medically acceptable form contraception Subjects history human immunodeficiency virus ( HIV ) , active hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) infection Subjects active bacterial infection clinically significant opinion Investigator Subjects history splenectomy Subjects unresolved meningococcal disease Subjects unresolved systemic bacterial fungal infection Subjects know suspect hereditary complement deficiency ( example , limit : aHUS , PNH ) Subject current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin situ carcinoma cervix treat appropriately Subject history believe Investigator use illicit drug ( ) and/or abuse alcohol within 3 month prior screen Subject psychiatric physical illness opinion Investigator would interfere ability subject participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DGF</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Kidney</keyword>
	<keyword>Kidney Transplantation</keyword>
	<keyword>eGFR</keyword>
	<keyword>Complement</keyword>
	<keyword>Eculizumab</keyword>
</DOC>